Planning and Monitoring of Equivalence Studies
- 1 June 1990
- journal article
- research article
- Published by JSTOR in Biometrics
- Vol. 46 (2) , 329-336
- https://doi.org/10.2307/2531438
Abstract
Demonstrating therapeutic equivalence of two treatments is the goal of many clinical trials. For instance, when the toxicity of an effective standard treatment is of concern, much effort is devoted to developing new therapies that would be both as effective and less toxic. In this paper we review the special characteristics of these trials and describe sequential monitoring of equivalence studies using repeated confidence intervals. We show how sequential monitoring may be of particular value in this setting and critically discuss the choice of some important design parameters. We also provide tables for use when planning a sequential equivalence trial.This publication has 6 references indexed in Scilit:
- Statistical Problems in the Reporting of Clinical TrialsNew England Journal of Medicine, 1987
- Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six WeeksNew England Journal of Medicine, 1987
- Confidence Intervals for Reporting Results of Clinical TrialsAnnals of Internal Medicine, 1986
- Designs for group sequential testsControlled Clinical Trials, 1984
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978
- A RANDOMISED TRIAL OF HOME-VERSUS-HOSPITAL MANAGEMENT FOR PATIENTS WITH SUSPECTED MYOCARDIAL INFARCTIONThe Lancet, 1978